Mi az ára Jacobio Pharmaceuticals Group Co., Ltd. (1167)

Jacobio Pharmaceuticals Group Co., Ltd. (1167) ára $0.84111496

Mi a Jacobio Pharmaceuticals Group Co., Ltd. (1167 piaci tőkésítése)

Jacobio Pharmaceuticals Group Co., Ltd. piaci tőkésítése (1167) $657.90M

Jacobio Pharmaceuticals Group Co., Ltd. (1167) Működési Eredményhányad

Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, JAB-3312 and JAB-3068, which are being investigated for esophageal cancer. Also in development is JAB-8263, a small molecule designed to inhibit BET family proteins that regulate MYC transcription, aiming to treat a range of cancers, alongside JAB-21822, an oral small molecule specifically targeting the mutant KRAS G12C protein. Jacobio is further advancing JAB-BX102, a humanized inhibitory antibody against human CD73, intended for treating PD-1 resistant cancers. Other pipeline assets include JAB-6343, an inhibitor targeting fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma exhibiting FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, which targets a tumor metabolic pathway for solid tumor treatment; and JAB-BX300, a molecular antibody designed to target the RAS pathway for pancreatic and other solid tumors with KRAS mutations. The company maintains a strategic partnership with AbbVie Ireland Unlimited Company for the development and commercialization of SHP2 inhibitors. Established in 2015, Jacobio Pharmaceuticals is headquartered in Beijing, China.

Év	Működési árrés	Változtassa meg
Nincs elég adat a megadott dátumokhoz.

Év

Működési árrés

Változtassa meg

Nincs elég adat a megadott dátumokhoz.

Vállalat	Működési árrés	Működési árrés különbség	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
CSL Limited CSL.AX	25.72%	-	AU
Moderna, Inc. MRNA.US	-149.01%	-	US
Lonza Group AG LONN.SW	0.00%	-	CH

Vállalat

Működési árrés

Működési árrés különbség

Ország